cortisol suppression as clinical end­point [Design Issues]

posted by lizhao – US, 2015-12-03 00:00 (3859 d 16:01 ago) – Posting: # 15688
Views: 11,594

Dear all,

what I am doing right now is using population based clinical trial simulations to prove that cortisol suppression is not a good clinical endpoint to show systemic bioequivalence.

My simulator could simulate crossover BE trials including both PK profiles and the corresponding cortisol profiles. Right now, based one the simulation results, even if I set Test and Reference products to be exactly the same, the probability of passing BE using cortisol suppression as a clinical endpoint is still very low.



I do need your guys' input so I am confident that I am doing the bioequilvance test in the right way.

My questions are 1: when compare cortisol suppression profiles of Test and Reference products, should I compare directly the cortisol suppression profiles of these products, or I have to do the "dose-scale" approach. Which means translate cortisol suppression back onto PK scale using dose-response curve?



2. What doses are usually being used for conducting cortisol suppression? ED50?


Thanks!!!!

Li

Complete thread:

UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,571 registered users;
329 visitors (0 registered, 329 guests [including 23 identified bots]).
Forum time: 17:01 CEST (Europe/Vienna)

Don’t compromise yourself.
You are all you’ve got.    Janis Joplin

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5